Insights Center
Thought leadership, news, events — you will find them all here, right at your fingertips. We’ve consolidated the firm’s most popular content in one, easy to search location. Enter a key word or phrase to find pertinent blog posts, articles, press releases, and upcoming events.
Mintz Viewpoints
Showing 1409 - 1416 of 11440 results
Energy & Sustainability Event Highlights — December 2022
December 13, 2022| Article| Viewpoint
New EU-US Data Privacy Framework
December 13, 2022| Blog| Viewpoint
Issuer Data Standards: A Natural Evolution Or A Dumbing Down?
December 13, 2022| News
Is Antitrust ESG's Achilles Heel ? House Republicans Think So.
December 13, 2022| Blog| Viewpoint
Newly Enacted Federal “Speak Out Act” Limits Use of Some Sexual Harassment NDAs
December 9, 2022| Blog| Viewpoint
Partnering and Giving Back With Clinic in a Box®
December 8, 2022| Article| Viewpoint
MintzTech Connect: All Things Technology — December 2022
December 7, 2022| Article| Viewpoint
News & Press Releases
Venture Mega-Rounds Return to Biotech
September 26, 2024
Member Cheryl Reicin was quoted in WSJ Pro Venture Capital in an article about how venture mega rounds are becoming more frequent in the biotech industry. Specifically, Cheryl discusses the need for startups to be aware of the pressures and implications that may come from larger funding rounds.
Lenovo’s Setback in Ericsson ITC Case May Impact Other SEP Disputes
September 26, 2024
Intellectual Property Division Chair Michael Renaud was quoted by IAM in an article about the ITC case between Ericsson and Lenovo and its potential implications for FRAND negotiations. While most ITC cases involving Standard Essential Patents (SEPs) have resulted in no violation findings, this case could change that.
Mintz Ranked in 2025 Edition of Chambers Canada
September 26, 2024
Mintz announced that it has been ranked in the 2025 edition of Chambers Canada. The firm was rankedin both the Life Sciences and Cannabis Law categories. Six attorneys were also ranked in individual categories including Life Sciences, Private Equity, Investment Funds, Cannabis, and Pensions & Benefits.